This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
22 Feb 2012

Jubilant Biosys & Mnemosyne Pharmaceutical Ink Drug Discovery Pact

The collaboration will leverage capabilities across medicinal chemistry, NMDA receptor pharmacology, electrophysiology, computational chemistry and DMPK and in vivo pharmacology.

Jubilant Biosys, a subsidiary of Jubilant Life Sciences Ltd, and Mnemosyne Pharmaceutical, a US-based privately held biotechnology company, have signed a drug discovery collaboration to identify preclinical candidates for neuropsychiatric diseases.

 

Mnemosyne will apply its NMDA receptor pharmacology expertise, supported by Jubilant's translational center in Malvern, PA and facilities based in India. The collaboration will leverage capabilities across medicinal chemistry, NMDA receptor pharmacology, electrophysiology, computational chemistry and DMPK and in vivo pharmacology. Mnemosyne will own all IP generated and will be responsible for clinical development and commercialization.
 
Sri Mosur, chief executive officer and president of Global Drug Discovery & Development at Jubilant,

Related News